Osmosis Investment Management UK Ltd bought a new position in shares of Merck KGaA (OTCMKTS:MKGAF – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 39,005 shares of the company’s stock, valued at approximately $5,012,000.
Other hedge funds also recently added to or reduced their stakes in the company. Frazier Financial Advisors LLC acquired a new stake in shares of Merck KGaA during the 2nd quarter valued at approximately $25,000. Rakuten Securities Inc. acquired a new stake in shares of Merck KGaA in the 2nd quarter worth approximately $27,000. Solstein Capital LLC purchased a new position in Merck KGaA in the 2nd quarter valued at approximately $33,000. Burk Holdings LLC purchased a new position in Merck KGaA in the 2nd quarter valued at approximately $39,000. Finally, Bard Associates Inc. acquired a new position in Merck KGaA during the second quarter worth $60,000. 0.10% of the stock is owned by hedge funds and other institutional investors.
Merck KGaA Price Performance
MKGAF opened at $163.21 on Monday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.84 and a current ratio of 1.31. The company has a market cap of $21.09 billion, a price-to-earnings ratio of 24.92 and a beta of 0.96. Merck KGaA has a one year low of $116.68 and a one year high of $175.56. The business’s fifty day moving average is $162.62 and its two-hundred day moving average is $148.44.
About Merck KGaA
Merck KGaA, headquartered in Darmstadt, Germany, is a long-established multinational chemical and pharmaceutical company with roots dating back to 1668. Operating under the brand Merck Group (and using distinct consumer-facing names in certain regions to avoid confusion with other companies of similar name), the company is privately controlled by the Merck family and organizes its activities across multiple business units that serve customers in Europe, the Americas, Asia-Pacific and beyond.
The company’s operations are organized mainly into three businesses.
Featured Stories
- Five stocks we like better than Merck KGaA
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
- 3 Closed-End Funds to Maximize Dividend Payments
- Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy?
- $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
